S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
Log in

NASDAQ:MITOStealth BioTherapeutics Stock Price, Forecast & News

$1.56
+0.18 (+13.04 %)
(As of 04/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.38
Now: $1.56
$1.74
50-Day Range
$0.97
MA: $1.63
$3.07
52-Week Range
$0.90
Now: $1.56
$15.84
Volume316,500 shs
Average Volume615,354 shs
Market Capitalization$54.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MITO
CUSIPN/A
CIKN/A
Phone617-600-6888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.09 million
Book Value$0.49 per share

Profitability

Net Income$-71,730,000.00

Miscellaneous

Employees57
Market Cap$54.65 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter.


Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

How has Stealth BioTherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MITO shares have decreased by 1.8% and is now trading at $1.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Stealth BioTherapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stealth BioTherapeutics.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Stealth BioTherapeutics.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) announced its quarterly earnings results on Thursday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). View Stealth BioTherapeutics' earnings history.

What price target have analysts set for MITO?

5 brokers have issued 1 year price objectives for Stealth BioTherapeutics' shares. Their forecasts range from $5.00 to $10.00. On average, they expect Stealth BioTherapeutics' share price to reach $8.20 in the next year. This suggests a possible upside of 425.6% from the stock's current price. View analysts' price targets for Stealth BioTherapeutics.

Has Stealth BioTherapeutics been receiving favorable news coverage?

Media headlines about MITO stock have been trending very negative on Thursday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stealth BioTherapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutStealth BioTherapeutics.

Who are some of Stealth BioTherapeutics' key competitors?

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Tesla (TSLA), Aytu Bioscience (AYTU), Okta (OKTA), Opko Health (OPK), Paypal (PYPL), AbbVie (ABBV), Aimmune Therapeutics (AIMT) and Capricor Therapeutics (CAPR).

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:
  • Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 54)
  • Mr. Daniel E. Geffken, Interim Chief Financial Officer (Age 62)
  • Mr. Mark J. Bamberger, Chief Scientific Officer (Age 66)
  • Mr. Henry Hess, Chief Legal Counsel
  • Dr. Ben R. Bronstein, Chief Medical Officer (Age 69)

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an IPO on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $1.56.

How big of a company is Stealth BioTherapeutics?

Stealth BioTherapeutics has a market capitalization of $54.65 million and generates $21.09 million in revenue each year. The company earns $-71,730,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Stealth BioTherapeutics employs 57 workers across the globe. View additional information about Stealth BioTherapeutics.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is http://www.stealthbt.com/.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel